Showing results (141-150 of 155) with videos related to

Sort By:
Pageof 16
The Oncologist|May 17, 2022
Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603Yasuyuki Kawamoto, Satoshi Yuki, Kentaro Sawada, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2017
The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancerEric Van Cutsem, Robert J Mayer, Stéphanie Laurent, et al.
Breast Cancer Research and Treatment|July 20, 2026
Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B)Meiko Nishimura, Takahiro Kogawa, Keiji Sugiyama, et al.
Cancer Chemotherapy and Pharmacology|May 24, 2021
Phase II study of trifluridine/tipiracil (TAS-102) therapy in elderly patients with colorectal cancer (T-CORE1401): geriatric assessment tools and plasma drug concentrations as possible predictive biomarkersMasanobu Takahashi, Yasuhiro Sakamoto, Hisatsugu Ohori, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 29, 2023
Phase III study of bilayer sustained-release tramadol tablets in patients with cancer pain: a double-blind parallel-group, non-inferiority study with immediate-release tramadol capsules as an active comparatorMasaharu Shinkai, Noriyuki Katsumata, Shinichi Kawai, et al.
Clinical Colorectal Cancer|September 3, 2018
Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical TrialsTakayuki Yoshino, Kentaro Yamazaki, Eiji Shinozaki, et al.
BMJ Open|May 9, 2022
Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancerShintaro Nakano, Yasuyuki Kawamoto, Satoshi Yuki, et al.
Targeted Oncology|March 1, 2024
A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018GToshihiko Matsumoto, Yoshiyuki Yamamoto, Masahito Kotaka, et al.
Future Oncology (London, England)|February 17, 2015
Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPPYoshimitsu Kobayashi, Yoshito Komatsu, Satoshi Yuki, et al.
Targeted Oncology|January 9, 2024
Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal CancerYu Sunakawa, Yasutoshi Kuboki, Jun Watanabe, et al.
Pageof 16